FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely ophthalmology, and can be used for ensuring regression of ocular neovascularisation. That is ensured by introducing a composition containing a therapeutically effective amount of a receptor tyrosine kinase inhibitor which blocks tyrosine autophosphorylation of VEGF receptor-2 with IC50≤ 10 nM and VEGF receptor-1 with 1C50≤ 10 nM and PDGFR with 1C50≤ 100 nM.
EFFECT: invention provides strong antiangiogenic effectiveness, ensured avoiding visual acuity loss related to ocular neovascularisation.
7 cl, 5 tbl, 8 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING OCULAR ANGIOGENESIS, RETINAL HYPOSTASIS, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2396956C2 |
| SUNITINIB-BASED COMPOSITIONS AND METHODS FOR USING THEM FOR TREATING EYE DISEASES | 2015 |
|
RU2729731C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| N-[4-(1-CYANOCYCLOPENTYL)PHENYL]-2-(4-PYRIDYLMETHYL)AMINO-3-PYRIDINE CARBOXAMIDE SALTS | 2009 |
|
RU2499796C2 |
| COMPOSITIONS AND METHODS OF SPHINGOSINE-1-PHOSPHATE BINDING | 2007 |
|
RU2460541C2 |
| METHOD FOR STIMULATING NEOVASCULARISATION OF RETINA AND OPTIC NERVE IN RABBITS | 2009 |
|
RU2408083C1 |
| INHIBITORS OF HISTONDEACETYLASE FOR TREATMENT OF OPHTHALMOLOGIC NEOVASCULAR DISTURBANCES AND DISEASES | 2003 |
|
RU2352337C2 |
| RECOMBINANT ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), OBTAINED BY VARIABLE REGION MUTAGENESIS | 2011 |
|
RU2557309C2 |
